2010-02-26
ASH has responded to
two federal requests regarding BCR-ABL1 mutation testing in chronic myeloid
leukemia. The Agency for Health Care Quality and Research (AHRQ) requested
comment on a technology assessment: Pharmacogenomic Tests for Cancer Treatment
Technology Assessment. ASH commented that there is compelling evidence that kinase
domain mutations predict response to TKI therapy. In addition, the Medicare
Evidence Development and Coverage Advisory Committee (MedCAC) requested
testimony at its meeting on the same subject. ASH testimony stated that BCR-ABL1 testing is recognized in
the hematologic community as being not only justified but necessary for
candidates who are receiving imatinib and for monitoring during therapy. It is
important for ASH to respond to these types of information requests because the
AHRQ Technology Assessment and the MedCAC meeting may impact reimbursement for
this test.
back to top
